NEO GENOMICS

# Test Catalog

**Diagnostic. Prognostic. Predictive. Predisposition.**



# IDHNow for AML

## Alternative Name
IDH1/IDH2 Mutation Analysis by PCR, Sponsored Testing Program (4571X)

## Methodology
Molecular

## Test Description
Detection of mutations at IDH1 codons R132X and R100Q and at IDH2 codons R140X and R172X is performed using real-time PCR. IDH1 and IDH2 are analyzed concurrently.

This test is available through the Servier-sponsored IDH testing program initiative called IDHNow for AML. A separate test form is required. Please visit the IDHNow for AML page for more information and to download the Test Request Form.

## Clinical Significance
Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) and IDH2 genes have been identified in a variety of tumors including central nervous system gliomas, cholangiocarcinoma, acute myeloid leukemia, blast-phase myeloproliferative neoplasms (MPNs) and chronic-phase primary myelofibrosis (PMF). Per professional practice guidelines, testing for IDH mutations has diagnostic and prognostic implications in the workup of gliomas and guides therapy selection in AML. AML patients with IDH mutations may respond to venetoclax-based therapy or IDH inhibitors.

## Specimen Requirements
- Bone marrow: 2 mL in EDTA tube.
- Peripheral blood: 5 mL in EDTA tube.

## Storage & Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Slides can be packed at room temperature.

## CPT Code(s)*
Inquire for Testing Program details.

## New York Approved
Yes

## Level of Service
Global

## Turnaround Time
5 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

Rev. 121224